Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Upper GI Tract Bleeding: Hematemesis, Hematochezia, or Melena?
From Risk Stratification to Post-Endoscopic Management
- Obesity, Nutrition, and Mental Health
Depression, Binge Eating, Internalized Stigma
- From Hypertension to Heart Failure?
When and how to intervene
- Switzerland's First PTH Replacement Therapy
Palopegteriparatide for Chronic Hypoparathyroidism
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Quitting smoking reduces cardiovascular risks
Offer professional support
- CKD and High Blood Pressure
Keeping an Eye on Bidirectional Interactions
- Atherosclerotic Coronary Plaques in High-Risk Patients